In this article
Cyspera Intensive is a rinse-off product marketed for uneven tone and persistent pigmentation. Its current manufacturer page identifies cysteamine 7%, a detail that matters when comparing it with older cysteamine studies, a different Cyspera product or a prescription hydroquinone combination.
We checked the official product page and primary research abstracts on September 27, 2026. This review reports the published offer and its evidence limits; it does not describe personal use or a clinician's endorsement. CoreAge Rx is our sponsor and receives the first commercial placement, which is separate from the assessment of Cyspera's record below.
Match the exact name before using a study
The page calls this product Cyspera Intensive and lists cysteamine at 7%. Its ingredient list includes cysteamine hydrochloride, isobionic-amide, glycolic acid, moisturizing-base ingredients, vitamin C derivatives and fragrance, among other components. Reading only the word cysteamine leaves out much of the preparation a person would actually put on their skin.
The brand also sells Sensitive, Ageless and Total Skin products. Those names should not be used interchangeably when checking ingredients or price. A recommendation to pair Intensive with another product is a commercial routine suggestion, not proof that the second purchase is necessary for every reader or that each item has been evaluated in the same controlled trial.
The current list does not name hydroquinone. That is a formulation distinction, not a guarantee of comfort, pregnancy suitability or superior results. Our ingredient comparison guide explains why different pigment ingredients do not share a simple percentage-based potency scale.
The advertised $180 is a product price
The official page displays $180 and says tax is included, with shipping calculated at checkout. That is the visible product offer at the time of review. We did not complete checkout, verify shipping to a particular address or establish a personal total. Temporary bundles elsewhere on the site should not replace the standalone item's terms.
A bottle price also is not a monthly treatment cost. The extracted product record did not establish a personal supply duration or enough information to calculate one. The amount used, area addressed and product instructions would affect that discussion; this review does not invent a number of months to make the price look comparable with a prescription plan.
Use the dark-spot cost guide to separate an item price from clinician fees, automatic refills or an advertised supply-plan equivalent. A nonprescription checkout and a prescribed treatment service are different purchases, even when both appear in searches for dark-spot creams.
Rinse-off means the format needs attention
Intensive is described as a short-contact, rinse-off cream. It should not be relabeled as an ordinary leave-on moisturizer simply because both come in a cream format. Read the current package directions and ask a qualified professional how it fits alongside an existing prescription or a history of irritation.
The manufacturer's page describes an intensive phase and later maintenance, and promotes changes in as little as four weeks. Those are manufacturer instructions and claims. They do not establish a personal treatment window, a diagnosis or the time at which a particular reader should expect visible change. This article does not supply a substitute application schedule.
The presence of fragrance, glycolic acid or other ingredients is relevant when reviewing a previous reaction, without proving that any one of them will cause a problem. A full product list is more useful than assuming that hydroquinone-free means inert. Our care and follow-up guide helps organize that discussion.
A small hydroquinone comparison has important limitations
One randomized, double-blinded trial compared cysteamine cream with hydroquinone cream over sixteen weeks. It recruited twenty participants; fourteen completed, including five in the cysteamine group and nine in the hydroquinone group. The public abstract reports an intention-to-treat reduction in modified Melasma Area and Severity Index of 21.3% and 32%, respectively.
The difference was not statistically significant. That result does not prove the products were equivalent or that cysteamine is superior. A small study with uneven completion has limited ability to resolve between-group differences. The authors described hydroquinone as generally better tolerated and called for larger studies.
These are melasma severity results, not a promise that a current bottle of Cyspera Intensive will remove the same percentage of a reader's spots. The abstract alone does not establish that the product sold today, with its current concentration and complete base, is the exact preparation evaluated. We did not retrieve the full article to resolve every formulation and methodology detail.
Another trial used 5%, not the current 7% description
A separate double-blind randomized study enrolled fifty people with epidermal melasma and compared cysteamine 5% with a modified Kligman formula containing hydroquinone, retinoic acid and betamethasone. The abstract reports a greater reduction in its melasma score with cysteamine at the assessed time points over four months, along with better tolerability in that comparison.
That comparator differs from hydroquinone alone and from CoreAge's Spot On formula. It also is not automatically identical to an approved triple-combination product. Changing the comparison changes the question the trial answers. The two abstracts should not be flattened into a single claim that cysteamine always works better or always irritates less.
Most importantly for this purchase, 5% study evidence cannot be silently promoted into finished-product proof for the current 7% Intensive formulation. A higher listed concentration does not establish a greater benefit, an equivalent safety profile or the best choice for someone's skin. The full preparation and the actual clinical setting remain relevant.
Keep the diagnosis ahead of the alternative ingredient
Cysteamine may be a topic to discuss when a clinician is considering pigment-treatment options, but choosing a hydroquinone-free product does not answer why a dark area appeared. Our guide to different kinds of spots separates melasma, post-inflammatory marks and other lesions that may need assessment before treatment.
Sun protection and avoiding unnecessary irritation remain part of the conversation. A manufacturer claim about multiple biological pathways does not replace those practical measures or demonstrate that a product suits every skin tone, body area or existing condition. The sunscreen guide explains the label details to review alongside melasma care.
Cyspera Intensive's current record provides a clear ingredient concentration, a rinse-off format and a visible item price. Its research background requires more care: small studies, differing comparators and a concentration mismatch limit what can be promised about the exact product. Those are useful facts to take to a professional discussion, without treating this review as a prescription to buy or a reason to replace an existing treatment on your own.
THE SOURCE MATERIAL
Read the originals.
Source retrieval dates appear with each record below. A commercial page supports offer details; it does not independently validate the treatment claims.
- American Academy of Dermatology — Melasma self-care ↗
Guidance on daily protection, visible light, tinted sunscreen, and avoiding irritating products.
Source checked: 2026-09-27
- Cyspera — Intensive current product offer ↗
Official page lists cysteamine 7%, rinse-off format, full INCI and $180 with tax included/shipping at checkout. No exact current 7% finished-product trial, order total or personal supply duration verified.
Source checked: 2026-09-27
- Cysteamine versus hydroquinone — randomized trial abstract ↗
Primary research public abstract:20 recruited,14 completed over 16weeks, nonsignificant difference in mMASI and better hydroquinone tolerability. Not equivalence proof; exact current Cyspera 7% formula not established.
Source checked: 2026-09-27
- Cysteamine 5% versus modified Kligman formula — trial abstract ↗
Primary research abstract:50 participants, four-month comparison with hydroquinone/retinoic-acid/betamethasone mixture. Different concentration and comparator from the current retail product and Spot On; full paper not retrieved.
Source checked: 2026-09-27